Filtern
Volltext vorhanden
- ja (27)
Gehört zur Bibliographie
- ja (27)
Erscheinungsjahr
Dokumenttyp
Sprache
- Englisch (27)
Schlagworte
- T cells (4)
- GvHD (2)
- Multiple myeloma (2)
- alloreactive T cells (2)
- cancer (2)
- immune cells (2)
- mouse models (2)
- regulatory T cells (2)
- Activation (1)
- Allogeneic stem cell transplantation (1)
Institut
- Medizinische Klinik und Poliklinik II (25)
- Pathologisches Institut (7)
- Institut für Virologie und Immunbiologie (6)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (5)
- Kinderklinik und Poliklinik (5)
- Graduate School of Life Sciences (4)
- Theodor-Boveri-Institut für Biowissenschaften (4)
- Rudolf-Virchow-Zentrum (3)
- Neurochirurgische Klinik und Poliklinik (2)
- Abteilung für Funktionswerkstoffe der Medizin und der Zahnheilkunde (1)
Sonstige beteiligte Institutionen
EU-Projektnummer / Contract (GA) number
- 825575 (1)
Immune checkpoint blockade therapy is beneficial and even curative for some cancer patients. However, the majority don’t respond to immune therapy. Across different tumor types, pre-existing T cell infiltrates predict response to checkpoint-based immunotherapy. Based on in vitro pharmacological studies, mouse models and analyses of human melanoma patients, we show that the cytokine GDF-15 impairs LFA-1/β2-integrin-mediated adhesion of T cells to activated endothelial cells, which is a pre-requisite of T cell extravasation. In melanoma patients, GDF-15 serum levels strongly correlate with failure of PD-1-based immune checkpoint blockade therapy. Neutralization of GDF-15 improves both T cell trafficking and therapy efficiency in murine tumor models. Thus GDF-15, beside its known role in cancer-related anorexia and cachexia, emerges as a regulator of T cell extravasation into the tumor microenvironment, which provides an even stronger rationale for therapeutic anti-GDF-15 antibody development.